Clinical trial
A Phase 2 Trial of RAD001(Everolimus) in Low and Intermediate-1 Risk Myelodysplastic Syndrome
NCT00809185 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Trial of RAD001(Everolimus) in Low and Intermediate-1 Risk Myelodysplastic Syndrome
- Lead sponsor
- Case Comprehensive Cancer Center
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 30, 2005
- Completion date
- March 31, 2009
- Enrollment
- 7 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.